Please login to the form below

Not currently logged in
Email:
Password:

MSL Group media exec joins GCI

Becky Lauer, senior vice president and director of broadcast media/global health at MSL Group, has joined GCI Health to serve as senior vice president, director of media

Becky Lauer, who spent the past 11 years at MSL Group as senior vice president and director of broadcast media/global health, has joined GCI Health to serve as senior vice president, director of media.

In her new role, she will be responsible for providing strategic counsel and support across all GCI Health's account teams; planning and assessing media strategies; and creating media angles to reach specific target audiences.

During her time at MSL Group, Lauer provided strategic media counsel and generated media placements for healthcare clients including Pfizer, Roche, Merck, Eli Lilly, Abbott, Bayer, Novartis, sanofi-aventis, Johnson & Johnson, Daiichi-Sankyo and Genentech.

She was responsible for media relations for all FDA hearings/approvals and crisis management for MSL's healthcare practice.

Before moving to the agency side and joining MSL, Lauer spent two decades as a producer in the US for CNN, Fox News and CBS Evening News with Dan Rather.

Lauer's move comes a week after MSLGroup hired Ogilvy's David Bashaw to serve as senior vice president, deputy healthcare practice director, MSL New York.

New York City-based GCI Health is WPP's only healthcare public relations company. It was formed in 2008 when WPP merged Cohn & Wolfe and GCI Group, bringing both agencies together under the C&W name and breaking out GCI Health as a separate global healthcare agency.

GCI Health serves healthcare companies such as Johnson & Johnson, Eli Lilly, Genentech and Merck in addition to hospitals, not-for-profit organisations and other institutions.

31st May 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Peter Howarth
Exploring the potential of eosinophils
GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils...
white house
Eliminating pharmaceutical rebates, is this déjà vu?
By Andrew Parece and Matthew Majewski...
Patients are ready to embrace decentralised clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...

Infographics